Persistence of anti-hypertensive effect after 'missed doses' of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life

British Journal of Clinical Pharmacology

Volumn 41, Issue 2, 1996, Pages 83-88

  Leenen, Frans H H ^a   Fourney, Anne ^a   Notman, Gail ^a   Tanner, Joanna ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b General Practice Research Group   (United Kingdom)

Author keywords

Calcium antagonists; Compliance; Duration of action; Hypertension

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEART RATE; HUMAN; HYPERTENSION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE;

EID: 0030027078     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1996.tb00164.x     Document Type: Article

References (19)

1. Haynes RB. Determinants of compliance: The disease and the mechanics of treatment. In Compliance in health care Haynes RB, Taylor DW, Sackett DL. Baltimore: John Hopkins University Press, 1979: 1-7.
2. Sharkness CM, Snow DA. The patient's view of hypertension and compliance. Am J Prev Med 1992; 8: 141-146.
3. Sacket DL. The hypertensive patient: Compliance with therapy. Can Med Ass J 1979; 121: 259-261.
4. Haynes RB, Gibson ES, Hackett BC, et al. Improvement of medication compliance in uncontrolled hypertension. Lancet 1976; i: 1265-1268.
5. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przyck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881-1884.
6. Sramek JJ, Cutler NR, Seifert RD, Luna AD. Compliance in hypertension: Daily vs twice daily. Am J Hypertension 1993; 6: 1063.
7. Levy G. A pharmacokinetic perspective on medicament noncompliance. Clin Pharmacol Ther 1993; 54: 242-244.
8. Elliott HL. Trough: Peak ratio and twenty-four-hour blood pressure control. J Hypertension 1994; 12 (suppl 5): S29-S33.
9. Guerrero D, Rudd P, Bryant-Kosling C, Middleton BF. Antihypertensive medication-taking. Investigation of a simple regimen. Am J Hypertension 1993; 6: 586-592.
10. Waeber B, Erne P, Saxenhofer H, Heynen G. Use of drugs with more than a twenty-four-hour duration of action. J Hypertension 1994; 12 (suppl 8): S67-S71.
11. Donnelly R, Elliott HL, Meredith PA, Kelman AW, Reid AL. Nifedipine: individual responses and concentration-effect relationships. Hypertension 1988; 12: 443-449.
12. Murdoch D, Heel RC. Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 1991; 41: 478-505.
13. Buckly MMT, Grant SM, Goa KL, McTavish D, Sorkin EM. Diltiazem: A reappraisal of its pharmacological properties and therapeutic use. Drugs 1990; 39: 757-806.
14. Szlachcic J, Hirsch AT, Tubau JF, Vollmer C, Henderson S, Massie BM. Diltiazem vs propranolol in essential hypertension: Responses of rest and exercise blood pressure and effects on exercise capacity. Am J Cardiol 1987; 59: 393-399.
15. Abernethy DR, Gutkowska J, Winterbottom LM. Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: Pharmacodynamics in relation to disposition. Clin Pharmacol Ther 1990; 48: 76-86.
16. Naylor WG, GU XH. [3H] Amlodipine binding to rat cardiac membranes. J Cardiovasc Pharmacol 1991; 17: 587-592.
17. Donnelly R, Meredith PA, Miller SHK, Howie CA, ELliott HL. Pharmacodynamic modeling of the antihypertensive response to amlodipine. Clin Pharmacol Ther 1993; 54: 303-310.
18. Zanchetti A. Trough and peak effects of a single daily dose of nifedipine gastrointestinal therapeutic system (GITS) as assessed by ambulatory blood pressure monitoring. J Hypertension 1994; 12 (suppl 5): S23-S27.
19. Sorkin EM, Clissold SP, Brogden RN. Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs 1985; 30: 182-374.